[1] Ozen S,Pistorio A,Iusan S M,et al.EULAR/PRINTO/PRES criteria for Henoch-Sch?nlein purpura,childhood polyarteritis nodosa,childhood Wegener granulomatosis and childhood Takayasu arteritis:Ankara 2008.Part II:Final classification criteria[J].Ann Rheum Dis,2010,69(5):798-806.
[2] Rostoker G.Sch nlein-henoch purpura in children and adults:diagnosis, pathophysiology and management[J].BioDrugs,2001,15(2):99-138.
[3] 何威逊. 第1讲:儿童紫癜性肾炎诊断和治疗进展[J].临床儿科杂志,2002,20(1):59-61.
[4] Riccioni G,Bucciarelli T,Mancini B,et al.Antileukotriene drugs:clinical application,effectiveness and safety[J].Curr Med Chem, 2007,14(18):1966-1977.
[5] 李秀梅,张达群.白三烯受体拮抗剂孟鲁司特钠治疗过敏性鼻炎的临床观察[J].中国医药科学,2012,2(8):30-31.
[6] 陈晓英.白三烯与儿童过敏性紫癜肾炎临床及病理相关研究[D].中南大学,2006.
[7] 李丽.过敏性紫癜的病因及发病机制研究进展[J].中国医药指南,2013,8(27):67-68.
[8] Petric R,Ford-Hutchinson A W.Elevated cysteinyl leukotriene excretion in experimental glomerulonephritis[J].Kidney Int,1994,46(5):1322-1329. |
